Atossa Therapeutics, Inc. (ATOS)

USD 0.99

(-4.81%)

Market Cap (In USD)

124.54 Million

Revenue (In USD)

-

Net Income (In USD)

-30.09 Million

Avg. Volume

960.15 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.72-2.31
PE
-
EPS
-
Beta Value
1.232
ISIN
US04962H5063
CUSIP
04962H506
CIK
1488039
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Steven C. Quay FCAP, M.D., Ph.D.
Employee Count
-
Website
https://www.atossatherapeutics.com
Ipo Date
2012-11-08
Details
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.